ACCESS TO MEDICINES

Because of austerity measures and weak growth, our ageing populations and rising healthcare costs due to new, expensive treatments, European healthcare faces unprecedented and growing pressures. To successfully address this challenge policy makers must recognise the fundamental importance and potential of generic, biosimilar and value-added medicines in ensuring the sustainability of European healthcare and enabling more patients to access treatment (up to 100% more/doubled access). So policy makers should face the reality that there is a cost of inaction in terms of undermining access to health... Its aims is to defend the sustainability of European health systems and take advantage of the contribution of generic, biosimilar and value-added medicines.